# US 2016/0355502 A1 · Cathepsin cysteine protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355502 A1
- Document ID: US20160355502A1
- Status: Published application
- Kind: A1
- Application number: 15/116,518
- Filed: 2015-02-06
- Published: 2016-12-08
- Earliest claimed: 2014-02-11
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Shawn Stachel; Daniel V. Paone; Jing Li; Anthony Ginnetti; Jianmin Fu; Shimin Xu
- Web page: https://patentgrep.com/patent/US20160355502A1

## CPC

- C07D 401/10: linked by a carbon chain containing aromatic rings
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

## Claims

### Claim 1

A compound of the formula:
wherein
R1 is hydrogen, C1-6 alkyl C2-6 alkenyl, C3-8 cycloalkyl or heterocyclyl, wherein said alkyl and alkenyl groups are optionally substituted with one to six substituents independently selected from the group consisting of hydroxy, C3-6 cycloalkyl, halo and R8; and wherein said cycloalkyl and heterocyclyl groups are optionally substituted with one or two substituents independently selected from the group consisting of C1-6 alkyl, halo, OR6 and keto;
R2 is hydrogen, C1-6 alkyl or C2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six substituents independently selected from the group consisting of hydroxy, C3-6 cycloalkyl, halo and R8;
or R1 and R2 can be taken together with the carbon atom to which they are attached to form a C3-6 cycloalkyl or heterocyclyl ring wherein said cycloalkyl and heterocyclyl rings are optionally substituted with one to two substituents independently selected from the group consisting of R6, C1-6 haloalkyl and halo;
each R is independently selected from the group consisting of halo, and C1-2 alkyl, wherein said alkyl group is optionally substituted with one to three halo; or
two R3 groups on adjacent carbons can be taken together with the carbon atoms to which they are attached to form a C3-4 cycloalkyl ring, wherein said ring is optionally substituted with one to three halo;
R4a is aryl or heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, cyano, R6, OR6 and R8;
R4b is hydrogen or C1-6 alkyl which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and O(C1-6 alkyl);
or R4a and R4b can be taken together with the atoms to which they are attached to form a 4 to 7 membered saturated or unsaturated ring wherein said ring is optionally substituted with one to two substituents independently selected from the group consisting of R6, C1-6 haloalkyl and halo;
R5 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C1-6 haloalkyl, aryl, heteroaryl, C3-8 cycloalkyl, heterocycyl, C(O)NR6R8, C(O)R8, NR6C(O)OR7 or SOmR6, wherein said aryl, heteroaryl, cycloalkyl and heterocycyl groups are optionally substituted with one to five substituents independently selected from the group consisting of C1-6 alkyl, halo, oxo, cyano, C1-6 haloalkyl, OR6, C(O)NR6R7, C(O)OR6, C(O)R6, ═NR6, ═NCN and SO, 6′
R6 is hydrogen or C1-6 alkyl, which is optionally substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, cyano, C1-3 haloalkyl, and O(C1-6 alkyl);
R7 is hydrogen or C1-6 alkyl. which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and O(C1-6 alkyl);
R8 is C3-8 cycloalkyl, aryl, heteroaryl or heterocyclyl, wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one to four substituents independently selected from the group consisting of halo, cyano, oxo, R6, OR6, NR6R7, C3-6 cycloalkyl, aryl, heteroaryl, heterocyclyl, SOmR6 and SF5;
m in an integer from zero to two;
p is an integer from zero to two;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is hydrogen or C1-3 alkyl, wherein said alkyl group is optionally substituted with one to six halo; R2 is hydrogen or C1-3 alkyl, wherein said alkyl group is optionally substituted with one to six halo; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1 wherein or R1 and R2 can be taken together with the carbon atom to which they are attached to form a C3-4 cycloalkyl ring; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1 wherein each R3 is independently selected from the group consisting of hydrogen, halo or methyl, or two R3 groups on adjacent carbons can be taken together with the carbon atoms to which they are attached to form a C3-4 cycloalkyl ring, wherein said ring is optionally substituted with one to three halo; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R4a is aryl, wherein said aryl group is optionally substituted with one to four substituents independently selected from the group consisting of halo, hydroxy, cyano, R6, OR6 and heteroaryl; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R4a is heteroaryl, wherein said heteroaryl group is optionally substituted with one to two substituents independently selected from the group consisting of halo, hydroxy, cyano and methyl; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R5 is heterocyclyl, C(O)R8 or SOmR6, wherein said heterocycyl group is optionally substituted with one to five substituents independently selected from the group consisting of C1-6 alkyl, halo, oxo, cyan; C1-6 haloalkyl, OR6, C(O)NR6R7, C(O)R6, ═NR6, ═NCN and SOmR6; or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1 which is:
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(4-cyanopiperidin-1-yl)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-methoxyphenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1S,3R,4R,6R) or (1R,3R,4R,6S)—N-(1-cyanocyclopropyl)-4-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol -3-yl)bi cyclo[4.1.0]heptane-3-cathoxamide;
(1R,3R,4R,6S) or (1S,3R,4R,6R)—N-(1-cyanocyclopropyl)-4-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)bicyclo[4.1.0]heptane-3-carboxamide;
(1R,2R)-1N-(1-cyanocyclopropyl)-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
isopropyl 3-(4-(3-((1R,2R)-2-(1-cyanocyclopropyl)carbamoyl)cyclohexyl)-1-(4-fluorophenyl)-1H-pyrazol-4-yl)phenyl)azetidine-1-carboxylate;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(6-methylpyridazin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(5-chloropyridin-3-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R, 5 S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5-fluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5-fluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-5,5-difluoro-2-(3-(4-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyridin-2-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(4-fluorophenyl)4-(4-(1-methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(4-fluorophenyl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(4-(4-(1-(tert-butylimino)-1-oxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1-(cyanoimino)-1-oxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)cyclohexanecarboxamide;
(1R,2R)—N—((R or S)-1-cyanoethyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S or R)-1-cyanoethyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R2R)—N—((R or S)-1-cyanoethyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S or R)-1-cyanoethyl)-4,4-difluoro-2-(1-(5-fluoropyridin-2-yl)-4(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-methyl-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5-fluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1 ,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-4,4-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridi n-2-yl)-1H-pyrazol-3-yl)4,4-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-4,4-difluorocyclohexanecarboxamide;
(1R2R)—N—((S)-1-cyano-2-methylpropyl)4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3 -yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyanoethyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-5-methyl-1H-pyrazol -3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(3-fluoropyridin-2-yl)-5-methyl-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-4,4-difluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(1-(3-fluoropyridin-2-yl)-5-methyl-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(1-(3-fluoropyridin)-2-yl)-5-methyl-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5-fluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5 S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl )cyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyanoethyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyano-2-methylpropyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N—((S)-1-cyanoethyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R2R,5 S)—N—((S)-1-cyano-2-methylpropyl)-5-fluoro-2-(1-(3-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R5S)—N—((S)-1-cyanoethyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-4-(1,1-dioxidothiomorpholino)phenyl)-5-(fluoromethyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1 ,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(4-(4-(1 ,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-(hydroxymethyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-(hydroxymethyl)-1H-1-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(5-(difluoromethyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyanoethyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((S)-1-cyano-2-methylpropyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)-5,5-difluorocyclohexanecarboxamide;
(1R2R)—N—((S or R)-1-cyano-3,3,3-trifluoropropyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N—((R or S)-1-cyano-3,3,3-trifluoropropyl)-2-(3-(4-(1,1-dioxidothiomorpholino)phenyl)pyrazolo[1,5-a]pyridin-2-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R and 1S,2S)—N-(cyanomethyl)-5,5-difluoro-2-(4-(4-(methylsulfonyl)phenyl)-1-phenyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R and 1S,2S)—N-(cyanomethyl)-5,5-difluoro-2-(1-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R and 1S,2S)—N-(cyanomethyl)-5,5-difluoro-2-(4-(4-(methylsulfonyl)phenyl)-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R and 1S,2S)—N-(cyanomethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R and 1S,2S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(cyanomethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1S,2S)—N-(cyanomethyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1S,2S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(morpholine4-carbonyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-fluorophenyl)-4-(4-(3-oxopiperazine-1-carbonyl)phenyl)-1H-pyrazol -3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(4-hydroxypiperidine-1-carbonyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(2-cyanophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(2-methoxyphenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(4-(methylsulfonyl)piperazine-1-carbonyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(3-(methylsulfonyl)azetidin-1-yl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R2R)-2-(1-(4-chlorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol3yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-(2-hydroxypropan-2-yl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-(2-hydroxypropan-2-yl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(2-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R2R)-2-(1-(3-chlorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol -3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-cyanophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(3-cyanophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(2-chlorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(4-cyano-2-methylphenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(2-chloro-4-cyanophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(4-chloro-2-cyanophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(2-cyano-4-fluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(2-cyano-4-methylphenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-4,4-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(3-cyano-4-fluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-(difluoromethoxy)phenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5 S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5-fluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2(4-(4-1,1-dioxidothiomorpholino)phenyl)-1-(4((S and R)-2,2,2-trifluoro-1-hydroxyethyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N(1-cyanocyclopropyl)-2-(1-(2,5-difluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(4-(4-(4-cyano-4-fluoropiperidin-1yl)phenyl)-1-(4-fluorophenyl)-1H-pyrazol -3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R or 1S,2S)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-4,4-dimethylcyclohexanecarboxamide;
(1S,2S, or 1R,2R)—N-(1-cyanocyclopropyl)-2-(4(4(1,1-dioxidothiomorpholino)phenyl-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-4,4-dimethylcyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(3,5-difluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazo1-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-1-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(2-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-(trifluoromethoxy)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(4-(1H-pyrazol-1-yl)phenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(2-(trifluoromethoxy)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R) or (1S,2S)—N-(1-cyanocyclopropyl)-2(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-dimethylcyclohexanecarboxamide;
(1S,2S) or (1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-5,5-dimethylcyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3,4,5-trifluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(2,4-difluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(4-cyano-2-fluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol -3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(2,6-difluorophenyl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)-2-(4-(4-(1-acetylazetidin-3-yl)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
3-(4-(3-((1R,2R)-2-((1-cyanocyclopropyl)carbamoyl)cyclohexyl)-1-(4-fluorophenyl)-1H-pyrazol-4-yl)phenyl)-N-methylazetidine-1-carboxamide;
3-(4-(3-((1R,2R)-2-((1-cyanocyclopropyl)carbamoyl)cyclohexyl)-1-(4-fluorophenyl)-1H-pyrazol-4-yl)phenyl)-N-(2,2,2-trifluoroethyl)azetidine-1-carboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(1H-indol-5-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1-(ethylimino)-1-oxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(4-fluorophenyl)-5-methyl-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(1-(isopropylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(4-fluorophenyl)-4-(4-(1-oxido-1-((2,2,2-trifluoroethyl)imino)thiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(3-fluoropyridin-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R2R)-2-(1-(5-chloropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)-2-(1-(3-chloro-5-fluoropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(3,5-difluoropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazol-3-yl)-4,4-difluorocyclohexanecarboxamide;
(1R2R)-2-(1-(5-chloropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl-N-(1-cyanocyclopropyl)-4,4-difluorocyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-4,4-difluorocyclohexanecarboxamide;
(1S,3R,4R,6R) or (1R,3R,4R,6S)—N-(1-cyanocyclopropyl)-4-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)bicyclo[4.1.0]heptane-3-carboxamide;
(1R,3R,4R,6S) or (1S,3R,4R,6R)—N-(1-cyanocyclopropyl)-4-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)bicyclo[4.1.0]heptane-3-carboxamide;
(1R,3R,4R,6S) or (1S,3R,4R,6R)-4-(1-(5-chloropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)bicyclo[4.1.0]heptane-3-carboxamide;
(1S,3R,4R,6R)or (1R,3R,4R,6S)-4-(1-(5-chloropyridin-2-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)-N-(1-cyanocyclopropyl)bicyclo[4. 1.0]heptane-3-carboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(5-fluoropyridin-2yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-2-yl)-5-methyl -1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R5S)—N-(1-cyanocyclopropyl)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-imino-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R,5S)—N-(1-cyanocyclopropyl.)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)-4-(4-(1-(methylimino)-1-oxidothiomorpholino)phenyl)-1H-pyrazol-3yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(pyrimidin-2-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(pyridazin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(6-methoxypyridazin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(pyridin-4-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(pyridin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(5-fluoropyridin-3-yl)-1H-pyrazol -3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(6-methoxypyridin-3-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(1-(2,5-difluoropyridin-3-yl)-4-(4-(1,1-dioxidothiomorpholino)phenyl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1-(2-hydroxypyrimidin-5-yl)-1H-pyrazol-3-yl)cyclohexanecarboxamide;
(1R,2R)—N-(1-cyanocyclopropyl)-2-(4-(4-(1,1-dioxidothiomorpholino)phenyl)-1′-methyl-1′H-[1,4′-bipyrazol]-3-yl)cyclohexanecarboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

A method of treating osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, atherosclerosis, obesity, glaucoma, chronic obstructive pulmonary disease, metastatic bone disease, hypercalcemia of malignancy or multiple myeloma in a mammal in need thereof with a compound of claim 1.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and another agent selected from the group consisting of: an organic bisphosphonate, a selective estrogen receptor modulator, an estrogen receptor beta modulator, an androgen receptor modulator, an inhibitor of osteoclast proton ATPase, an inhibitor of HMG-CoA reductase, an integrin receptor antagonist, or an osteoblast anabolic agent, vitamin D, a synthetic Vitamin D analogue, a Nonsteroidal anti-inflammatory drug, a selective cyclooxygenase-2 inhibitor, an inhibitor of interleukin-1 beta, a LOX/COX inhibitor and the pharmaceutically acceptable salts and mixtures thereof.

### Claim 12 (depends on 1)

A method of treating osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease. tooth loss bone fractures, rheumatoid arthritis osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, atherosclerosis, obesity, glaucoma chronic obstructive pulmonary disease, metastatic bone disease, hypercalcemia of malignancy or multiple myeloma in a mammal in need thereof with a compound of claim 1 and another agent selected from the group consisting of: an organic bisphosphonate, a selective estrogen receptor modulator, an androgen receptor modulator, an inhibitor of osteoclast proton ATPase, an inhibitor of HMG-CoA reductase, an integrin receptor antagonist, an osteoblast anabolic agent, vitamin D, a synthetic Vitamin D analogue, a Nonsteroidal anti-inflammatory drug, a selective cyclooxygenase-2 inhibitor, an inhibitor of interleukin-1 beta, a LOX/COX inhibitor and the pharmaceutically acceptable salts and mixtures thereof.
